the skinny on weight loss meds · reported weight loss drug length of trial total weight loss (kg)...
TRANSCRIPT
The Skinny on
Weight Loss
Meds
Kathy H. Sullivan, MSN,
APRN-BC, CDE
No Financial disclosures
Definition of obesity
World Health Organization (WHO)
Abnormal or excessive fat accumulation
that presents a risk to health
Chronic, progressive disease resulting from
multiple environmental and genetic factors
National Institutes of Health (NIH)
A BMI (Body Mass Index) of 30 and above
Prevalence
Global Crisis
65 % of the world’s population lives in
countries where overweight + obesity kill
more people than underweight
Approximately 500 million adults in the
world are affected by obesity
1 billion are affected by being overweight
Medical cost of obesity is reported to be
about $145 billion/year
Obesity Statistics
CDC
> 33% of the US population is obese
Non-Hispanic African Americans with the highest rates, followed by Hispanic population, Caucasions, and Asians
https://www.cdc.gov/nchs/data/databriefs/db219.pdf)PDF-704KB
Self-Reported Obesity Among U.S. Adults by State and Territory, BRFSS, 2011
Prevalence estimates reflect BRFSS methodological changes started in 2011. These estimates should not be compared to prevalence estimates before 2011.
*Sample size <50 or the relative standard error (dividing the standard error by the prevalence) ≥ 30%.
Self-Reported Obesity Among U.S. Adults by State and Territory, BRFSS, 2012
Prevalence estimates reflect BRFSS methodological changes started in 2011. These estimates should not be compared to prevalence estimates before 2011.
*Sample size <50 or the relative standard error (dividing the standard error by the prevalence) ≥ 30%.
Self-Reported Obesity Among U.S. Adults by State and Territory, BRFSS, 2013
Prevalence estimates reflect BRFSS methodological changes started in 2011. These estimates should not be compared to prevalence estimates before 2011.
*Sample size <50 or the relative standard error (dividing the standard error by the prevalence) ≥ 30%.
Self-Reported Obesity Among U.S. Adults by State and Territory, BRFSS, 2014
Prevalence estimates reflect BRFSS methodological changes started in 2011. These estimates should not be compared to prevalence estimates before 2011.
*Sample size <50 or the relative standard error (dividing the standard error by the prevalence) ≥ 30%.
Self-Reported Obesity Among U.S. Adults by State and Territory, BRFSS, 2015
Prevalence estimates reflect BRFSS methodological changes started in 2011. These estimates should not be compared to prevalence estimates before 2011.
*Sample size <50 or the relative standard error (dividing the standard error by the prevalence) ≥ 30%.
Self-Reported Obesity Among U.S. Adults by State and Territory, BRFSS, 2016
Prevalence estimates reflect BRFSS methodological changes started in 2011. These estimates should not be compared to prevalence estimates before 2011.
*Sample size <50 or the relative standard error (dividing the standard error by the prevalence) ≥ 30%.
Comorbid conditions of Obesity
include:
OSA
HLD
HTN
T2DM/GDM
Cancers
Infertility
Fatty Liver Disease
Depression
CVD
Endocrine Society Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Endocrine Society Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Evaluating the Obese Patient
History Age of onset of weight
gain Previous weight loss
attempts
Change in dietary patterns
History of exercise Current/past
medications
Smoking cessation Sleeping disorders Eating disorders Family history of obesity
Co-morbid conditions
PE
Measurements
Labs
Fasting
glucose/A1C
Lipid panel
TFTs
LFTs
BMP
Frequent patient FU
All patients prescribed weight loss
medications should be seen at least
monthly for the first three months, then at
least every three months
Best weight loss outcomes occur with
frequent face to face visits (on average
16 visits per year)
Endocrine Society Clinical Practice Guidelines
Weight Altering Medications Commonly taken by Patients
Medical condition Preferred Agents Agents with
weight gain as a
potential side
effect
Type 2 DM GLP1 agonists,
SGLT2 inhibitors,
MTF
Sulfonylureas,
TZDs, Insulin,
Mitglinides
Hypertension ACE-Inhibitors,
ARBs
Beta-blockers
Antidepressants Fluoxetine,
Citalopram,
Escitalopram,
Buproprion
TCA, Mirtazapine,
Paroxetine
Inflammatory
diseases
NSAIDS, disease
modifying anti-
rheumatic drugs
steroids
Weight Altering Meds, cont’d
Medical conditions Preferred Agents Agents with
Weight gain as a
potential side
effects
Anti-epileptic drugs Lamotrigine,
Levetiracetam,
Phenytoin
Gabapentin,
Pregabalin,
Valproic Acid
Anti-psychotics Ziprasidone,
Aripiprazole
Clozapine,
Olanzapine,
Quetiapine,
Risperidone,
Seroquel
Oral
Contraceptives
IUDs, barrier
methods
OCPs
Khan S, Horn DB, Still C. Insights into the Patient Population with Obesity. Bariatric Times. 2016; 13: Supplement C
The Role of Medications in Weight Loss
They do not work on their own !!
Need to incorporate lifestyle changes first….
The addition of a weight loss medication
will likely result in greater weight loss
Pharmacological Treatment
General Recommendations
BMI Recommendation
> 25 Lifestyle Management
> 27 with comorbids OR
> 30
Pharmacologic
> 35 with comorbids OR
> 40
Bariatric Surgery
Endocrine Society Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Three Major Groups of Medications:
Centrally acting medications that impair
dietary intake.
Medications that act peripherally to impair
dietary absorption
Medications that increase energy
expenditure.
There are 5 FDA approved drugs for
long term use for weight loss in the US
1. Phentermine/Topiramate (schedule IV)
2. Orlistat
3. Naltrexone/Buproprion
4. Liraglutide
5. Lorcaserin (schedule IV)
AACE/ACE Algorithm For The Medical Care of Patients With Obesity. 2016.
AACE/ACE Algorithm For The Medical Care Of Patients with Obesity. 2016.
Phentermine/Topiramate
(Qsymia) Dose: Starting dose 3.75 mg/23 mg, then on day 15 increase to
7.5 mg/46 mg daily x 12 weeks, if not lost 3% discontinue or escalate. If escalate, 11.25 mg/69 mg daily x 14 days, then 15 mg/92 mg x 12 weeks. If not lost at least 5% on higher dose, discontinue gradually.
Formulation: Capsule
MOA: GABA receptor modulation, norepinephrine releasing agent
Average Weight Loss: Recommended dose 6.6 kg / 14.5 lbs; high dose 8.6 kg / 18.9 lbs
Status: Approved in 2012 for chronic management
Side Effects: Paresthesia, constipation, dry mouth, insomnia, dizziness, altered sense of taste, nephrolithiasis
Contraindications: Pregnancy/breast feeding, glaucoma, hyperthyroidism, MAOI, sympathomimetics
Scheduled Medication
Orlistat
(Alli, Xenical)
Dose: Xenical Rx only – 120 mg p.o. q8hrs; Alli 60 mg p.o. q8hrs
Formulation: Capsule
MOA: Pancreatic and gastric lipase inhibitor
Average Weight Loss: 2.9 - 3.4 kg / 6.5 – 7.5 lbs
Status: Approved in 1999 for chronic management
Side Effects: Fecal incontinence, defecation, steatorrhea, fecal urgency, flatulence, decreased absorption of fat soluble vitamins
Contraindications: Warfarin, levothyroxine, malabsorption syndrome, pregnancy/breast feeding, cholestasis, antiepileptics, cyclosporine
Naltrexone/Bupropion
(Contrave)
Dose: Target dose 32 mg/360 mg achieved at start of week four. 8 mg/90 mg daily during week 1, increase by 1 tablet daily each week until 2 tablets twice daily.
Formulation: Extended Release Tablet
MOA: Combo is thought to regulate the dopamine reward system to help control eating patterns. Naltrexone specifically blocks opioid receptors. Bupropion increases dopamine activity.
Average Weight Loss: 4.8 %
Status: Approved in 2014 for chronic management Side Effects: GI, dizziness
Contraindications: Seizure disorder, eating disorder, MAOI, uncontrolled hypertension, drug/alcohol withdrawal
Liraglutide
(Saxenda)
Dose: 3 mg injected (0.6 mg x 1 week daily, increase by 0.6 mg weekly until 3 mg dose achieved)
Formulation: Injectable
MOA: GLP-1 agonist
Average Weight Loss: 5.8 kg
Status: Approved in 2014 for chronic management
Side Effects: GI, pancreatitis
Contraindications: Medullary thyroid cancer, MEN 2, insulin therapy
Above dosing not approved for diabetes management (Victoza)
Lorcaserin
(Belviq)
Dose: 10 mg p.o. BID or 20 mg p.o. daily
Formulation: Tablet, Extended release tablet
MOA: 5HT2c receptor agonist (anorexigenic neurons in hypothalamus)
Average Weight Loss: 3.6 kg / 7.9 lbs
Status: Approved in 2012 for chronic management
Side Effects: Nausea, dry mouth, dizziness, constipation
Contraindications: Pregnancy/breast feeding, use caution with other serotonergic medications
Phentermine (Adipex, Lomaira)
Dose: 15 – 37.5 mg/day in 1-2 divided doses; Lomaira 8 mg TID
Formulation: Capsule, Tablet, ODT
MOA: Norepinephrine releasing agent
Average Weight Loss: 3.5 kg / 7.9 lbs
Status: Approved for short term use (3 months)/ Approved in 1960s
Side Effects: Multiple
Contraindications: Anxiety, seizure, uncontrolled hypertension, history of heart disease, MAOI, pregnancy/breast feeding, glaucoma, hyperthyroidism, history of drug use, other sympathomimetics
Scheduled Medication
Phentermine, cont’d
Long term Phentermine use is OFF LABEL, but
used widely primarily due to its favorable
cost. It may be reasonable to continue
long-term treatment with Phentermine to
prevent weight gain as long as the OFF
LABEL use is disclosed to the patient, and
there are no serious CVD, psychiatric
disease, history of substance abuse of any
significant increase in HR or BP
Reported Weight Loss Drug Length of
Trial
Total
Weight
Loss (kg)
Percent
weight
loss
Cost
(USD/
month)
Phentermine 13 weeks 6.4 4 45
Orlistat > 52
weeks
5.3 4 45,
207
Lorcaserin 52 weeks 5.8 3 240
Phentermine/
Topiramate
> 52
weeks
10.2 9 195
Bupropion/
Naltrexone
>52
weeks
6.1 5 55
Liraglutide 3.0 mg 24 weeks 2.8 5 1000
References
1. Vilsboll et al, BMJ 2012, 344:d7771 5. Khera R et al, JAMA. 2016;315(22):2424-2434.
2. LeBlanc ES et al, Ann Intern Med, 2011, 155:434
3. UpToDate, accessed 9/17/16.
4. Yanovski SZ et al, JAMA 2014;311(1):74
Virtually all weight loss medications in the US
have the same thing in common….
Medication
Denied as 'Not a
Covered Benefit'
Monthly cost for self-pay (without coupon)
Medication # of pills cost
Qysmia caps 3.75/23 mg 30 $218.12
Qysmia caps 7.5/46 mg 30 $223.20
Qysmia caps 11.25/69 mg 30 $239.40
Qysmia caps 15/92 mg 30 $239.40
Alli 60 mg (OTC) 120 $77.93
Xenical 120 mg (Rx) 90 $748.22
Contrave tabs 8/90 mg 120 $333.58
Saxenda pen 18 mg/3ml 5 pens $1440.50
Belviq 10 mg 60 $317.93
Belviq 20 mg XR 30 $317.93
Monthly cost, cont’d
Medication # of pills cost
Phentermine 15 mg caps 30 $27.95
Phentermine 30 mg caps 30 $27.95
Phentermine 37.5 mg XR tabs 30 $19.95
Trokendi 25 mg XR 30 $332.00
Trokendi 50 mg XR 30 $412.00
Trokendi 100 mg XR 30 $822.38
Trokendi 200 mg XR 30 $1124.97
Serotonin Syndrome
Potentially life threatening condition associated with increased serotonergic activity in the
central nervous system
Clinical Diagnosis – no laboratory test to confirms
s/sx: mental status changes – anxiety, agitated delirium, restlessness and disorientation. Can also include diaphoresis, tachycardia, and
hyperthermia
Physical Examination findings
in Serotonin Syndrome
Tachycardia
Hypertension
Hyperthermia
Agitation
Dilated pupils
Tremors
Deep tendon
hyperreflexia
Ocular clonus
Inducible or spontaneous muscle clonus
Muscle rigidity
BL Babinski signs
Dry mucous membranes
Flushed skin
Increased bowel sounds
Majority of cases of serotonin syndrome present
within 24 hours and most within six hours of a
change or initiation of a drug
It is seen with therapeutic medication use,
inadvertent interactions
Observed in all age groups including newborns
and the elderly
SSRIs are the most common medications
associated with diagnosis
Estimate of Bariatric Surgery Numbers, 2011-2016
2011 2012 2013 2014 2015 2016
Total 158,000 173,000 179,000 193,000 196,000 216,000
RNY 36.7% 37.5% 34.2% 26.8% 23.1% 18.7%
Band 35.4% 20.2% 14% 9.5% 5.7% 3.4%
Sleeve 17.8% 33% 42.1% 51.7% 53.8% 58.1%
BPD/DS 0.9% 1% 1% 0.4% 0.6% 0.6%
Revisions 6% 6% 6% 11.5% 13.6% 13.9%
Other 3.2% 2.3% 2.7% 0.1% 2.3% 2.6%
Balloons 0.03 2.7
V-bloc 18
cases
ASMBS total bariatric procedures numbers from 2011, 2012, 2013, 2014,2015, and 2016 are based on the best estimation form available data (BOLD, ASC/MBSAQIP, National Inpatient Sample data and outpatient estimates)
Bariatric Procedures Performed at CCHS
2016 ~ 648 cases
59% sleeve
13% bypass
11 %
conversion/revision
17 % other
revision/band
removal
0.2% banding
2017 ~ 616 cases
62% sleeve
15 % bypass
9 %
conversion/revision
13 % other
revision/band
removal
0.8 % banding
0.5 % DS
Case study #1: 55 yo male with
metabolic syndrome
CC: Cannot lose weight despite personal training 3x/wk
FH: DM, CAD
Meds: Atenolol
Valsartan
Glipizide twice a day
Pioglitazone
MTF
Atorvastatin
Glargine Insulin
Data:
Wt 264 lbs
Ht 5’ 10”
BMI 38kg/m2
Waist 45 in
BP 150/95
A1C 7.2
FBG 150-175
To Chol 220
Trigs 300
LDL-C 130
HDL 40
Case #1, questions
1. Before starting a low-calorie diet, you
would want to stop/re-think:
1. Pioglitazone
2. Glipizide 5mg twice a day
3. Atenolol
4. Metformin 500 mg twice a day
5. Insulin 20 units at night
Case Study # 2:, 61 yo female with post
menopausal weight gain
Severe obesity – referred for surgery
Asthma, arthritis, fibromyalgia
Undiagnosed HTN
FH: HTN
Meds: Zafirlukast
Albuterol Inhaler
Metoprolol
Loratadine
Etodolac
paroxetine
Vitamin B, MVI, Calcium
Labs:
Wt: 200 lbs
Ht: 5’ 5”
BMI 33 kg/m2
Waist 34 in
BP 160/95
A1C 5.9
FBS 105
To Chol 250
Trigs 260
LDL 150
HDL 60
Case #2: Questions
Which comorbidities should improve with weight loss ?
1. Asthma
2. Arthritis
3. Fibromyalgia
4. HTN
Which of her medications can case weight gain ?
1. Zafirlukast
2. Loratadine
3. Etodolac
4. Paroxetine
Case Study # 3: 36 yo female referred to me
by bariatric surgeon for significant weight gain
following gastric bypass 2012
Complex medical history
MO, s/p gastric bypass
Depression, chronic migraine syndrome, fibromyalgia, cancer
No history of pancreatitis or personal/family h/o thyroid ca
Meds Cymbalta, Tizanidine, Prevacid, MVI, Zofran, Lamictal, Trazodone, Abilify, Nortriptyline, Advair, Colace, Proair, Calcium +D, Verapamil, Ropinirole, Lyrica, Meclizine, Tylenol w/codeine
Labs
Wt current: 352.5 lbs
Ht: 5’ 5”
BMI: 55.41
BP 110/78 HR 84
BUN 6 creat 0.75
To chol 213
LDL 141
HDL 53
Trigs 87
Glucose 80
Case # 3: questions
Given her medical history, which of these
weight loss medications would you start ?
1. Phentermine
2. Qysmia
3. Belviq
4. Saxenda
What do you do next ?
Conclusion
Obesity is a HUGE concern – locally,
nationally, and worldwide
Significant morbidity and mortality
contribute to health care costs
First line treatment should always be
aggressive lifestyle changes
Prescribe weight neutral medications
whenever possible for other disease states
Patients should understand that successful
treatment requires lifelong treatment
Conclusion, cont’d
So much that we didn’t get to talk about…. CDC guidelines for physical activity (150 mins/wk)
Behavioral Modification/therapy
Weight loss meds are not indicated during pregnancy, or lactation
pediatrics – Orlistat is approved for use in children 12 and older
Herbal Supplements
are not recommended as part of a weight loss program. They have
unpredictable amounts of active ingredients and unpredictable – and potentially harmful – side effects.”
www.NHLBI.NIH.gov
References Adult Obesity Facts. Centers for Disease Control and Prevention. https://www.cdc.gov/obesity/data/adult.html
Apovain CM, Aronne LJ, Bessesen DT, et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2015:100(2):342-362. doi:10.1210/jc.2014-3415.
Boyer EW. Serotonin Syndrome (Serotonin Toxicity). UpToDate. https://www.uptodate.com/contents/serotonin-syndrome-serotonin-toxicity. Last updated Aug 5, 2016. Accessed Jan 3, 2018.
Bray GA. Obesity in Adults: Drug Therapy. UpToDate. https:www.uptodate.com/contents/obesity-in-adults-drug-therapy. Updated Mar 25, 2016. Accessed Feb 9 2017.
Bray GA. Obesity in Adults: Prevalence, Screening, and Evaluation. UpToDate. https://www.uptodate.com/contents/obesity-in-adults-prevalence-screening-and-evaluation. Updated Jan 31, 2017. Accessed Jan 9, 2018.
Hamby O. Obesity Medication. Medscape. https://emedicine.medscpare.com/article/123702-medication. Updated Mar2, 2017. Accessed Sept 29, 2017.
Hahipah ZN, Nasr EC, Bucak, E, et al. Efficacy of Adjuvant Weight Loss Medication After Bariatric Surgery. American Society for Metabolic and Bariatric Surgery. 2018; 93-98. doi.org/10.1016/j.soard.207.10.02.
Khan S, Horn DB, Still C. Insights into the Patient Population with Obesity. Bariatric Times. 2016; 13: Supplement C
Kyle T, Kuehl B. Prescription Medication & Weight Gain – What You Need To Know. Obesity Action Coalition.
Neeland IJ, Poirer P, Depres JP. Cardiovascular and Metabolic Heterogenity of Obesity. Clinical Challenges and Implications for Management. Circulation. 2018; 1391-1406
Obesity. WHO. http//www.who.int/topics/obesityen/. Published 2017
Overweight & Obesity. Centers for Disease Control and Prevention. https//www.cdc.gov/obesity.adult.indexhtml. Published April 27, 2012
Primack, P. What to Expect from New Chronic Weight Management Medications.
Prescription Medications to Treat Overweight and Obesity. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/weight-managemnt/prescription-medication.
Rucker D, Padwal R, Li SK, et al. Long Term Pharmacotherapy for Obesity and Overweight: Updated Meta-analysis. BMJ. September 2007
Skversky R. Medical Weight-Loss: Dispelling the Myths.
State of Obesity in Delaware. State of Obesity.Org. https://stateof obesity.org/states/de
Yanovski SZ, Yanoski JA. Long-term Drug Treatment for Obesity. JAMA. 2014:311 (1):74-86. doi10.1001/jama.2013.281364.